Additionally, immunotherapies (anti-PD1/PD-L1 therapies), neoadjuvant chemotherapy, radiotherapy, and ERBB therapy were all suitable for treating BLCA with high PMEPA1 expression. This evidence concerns the gene EGFR and bladder transitional cell carcinoma.